Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

Original languageEnglish
Article numbere11053
JournalMedicine (United States)
Volume97
Issue number25
DOIs
Publication statusPublished - 2018 Jun 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa'. Together they form a unique fingerprint.

Cite this